Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Open Access
- 1 April 2013
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 123 (5), 2155-2168
- https://doi.org/10.1172/jci65780
Abstract
The mechanisms underlying adaptive resistance of melanoma to targeted therapies remain unclear. By combining ChIP sequencing with microarray-based gene profiling, we determined that ERBB3 is upregulated by FOXD3, a transcription factor that promotes resistance to RAF inhibitors in melanoma. Enhanced ERBB3 signaling promoted resistance to RAF pathway inhibitors in cultured melanoma cell lines and in mouse xenograft models. ERBB3 signaling was dependent on ERBB2; targeting ERBB2 with lapatinib in combination with the RAF inhibitor PLX4720 reduced tumor burden and extended latency of tumor regrowth in vivo versus PLX4720 alone. These results suggest that enhanced ERBB3 signaling may serve as a mechanism of adaptive resistance to RAF and MEK inhibitors in melanoma and that cotargeting this pathway may enhance the clinical efficacy and extend the therapeutic duration of RAF inhibitors.Keywords
This publication has 57 references indexed in Scilit:
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast CancerCancer Cell, 2011
- Using MACS to Identify Peaks from ChIP‐Seq DataCurrent Protocols in Bioinformatics, 2011
- Integrative genomics viewerNature Biotechnology, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- The ERBB3 receptor in cancer and cancer gene therapyCancer Gene Therapy, 2008
- Mechanism of Activation and Inhibition of the HER4/ErbB4 KinaseStructure, 2008
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002